BR112016007646A2 - forma cristalina anidra de cabazitaxel, uso da forma cristalina anidra de cabazitaxel, composição farmacêutica e processo para o preparo forma cristalina anidra de cabazitaxe - Google Patents

forma cristalina anidra de cabazitaxel, uso da forma cristalina anidra de cabazitaxel, composição farmacêutica e processo para o preparo forma cristalina anidra de cabazitaxe

Info

Publication number
BR112016007646A2
BR112016007646A2 BR112016007646A BR112016007646A BR112016007646A2 BR 112016007646 A2 BR112016007646 A2 BR 112016007646A2 BR 112016007646 A BR112016007646 A BR 112016007646A BR 112016007646 A BR112016007646 A BR 112016007646A BR 112016007646 A2 BR112016007646 A2 BR 112016007646A2
Authority
BR
Brazil
Prior art keywords
anhydrous
crystalline form
cabazitaxel
cabazitaxe
preparing
Prior art date
Application number
BR112016007646A
Other languages
English (en)
Other versions
BR112016007646B1 (pt
Inventor
Gambini Andrea
Ciceri Daniele
PETERLONGO Federico
Domenighini Luca
Cabri Walter
Original Assignee
Indena Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49447494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016007646(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Indena Spa filed Critical Indena Spa
Publication of BR112016007646A2 publication Critical patent/BR112016007646A2/pt
Publication of BR112016007646B1 publication Critical patent/BR112016007646B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção refere-se a uma nova forma cristalina anidra de cabazitaxel de fórmula (i), designada como forma h. um objeto adicional da presente invenção é um processo para o preparo da forma h mencionada acima por recristalização de cabazitaxel a partir de uma mistura de decanoil e octanoil triglicerídeos ou a partir de trioctanoato de glicerol. a forma h de cabazitaxel é útil para preparar cabazitaxel, sais de cabazitaxel e formas polimórficas deste. é também particularmente útil como medicamento, especialmente para o tratamento de cânceres.
BR112016007646-0A 2013-10-23 2014-10-09 Forma cristalina anidra de cabazitaxel, uso da forma cristalina anidra de cabazitaxel, composição farmacêutica e processo para o preparo forma cristalina anidra de cabazitaxe BR112016007646B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13189949.4 2013-10-23
EP20130189949 EP2865675A1 (en) 2013-10-23 2013-10-23 A crystalline anhydrous form of Cabazitaxel, process for the preparation and pharmaceutical compositions thereof
PCT/EP2014/071601 WO2015058961A1 (en) 2013-10-23 2014-10-09 A crystalline anhydrous form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
BR112016007646A2 true BR112016007646A2 (pt) 2017-08-01
BR112016007646B1 BR112016007646B1 (pt) 2022-12-27

Family

ID=49447494

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007646-0A BR112016007646B1 (pt) 2013-10-23 2014-10-09 Forma cristalina anidra de cabazitaxel, uso da forma cristalina anidra de cabazitaxel, composição farmacêutica e processo para o preparo forma cristalina anidra de cabazitaxe

Country Status (20)

Country Link
US (1) US9586919B2 (pt)
EP (2) EP2865675A1 (pt)
JP (2) JP2016534065A (pt)
KR (2) KR20160063356A (pt)
CN (1) CN105849093A (pt)
AU (1) AU2014339222B2 (pt)
BR (1) BR112016007646B1 (pt)
CA (1) CA2928305C (pt)
CL (1) CL2016000951A1 (pt)
DK (1) DK3060556T3 (pt)
ES (1) ES2645478T3 (pt)
HU (1) HUE035010T2 (pt)
IL (1) IL245260B (pt)
MX (1) MX363334B (pt)
PL (1) PL3060556T3 (pt)
PT (1) PT3060556T (pt)
RU (1) RU2672110C2 (pt)
SG (1) SG11201603168WA (pt)
SI (1) SI3060556T1 (pt)
WO (1) WO2015058961A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3010514A1 (en) 2016-01-15 2017-07-20 Zhuhai Beihai Biotech Co., Ltd. Compositions and formulations including cabazitaxel and human serum albumin
US11413265B2 (en) 2018-04-20 2022-08-16 Zhuhai Beihai Biotech Co., Ltd. Formulations and compositions of Cabazitaxel
WO2020249507A1 (en) * 2019-06-11 2020-12-17 Indena S.P.A. Anhydrous crystalline form of cabazitaxel, a process for its preparation and pharmaceutical compositions containing it

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
FR2771092B1 (fr) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
FR2859996B1 (fr) * 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
KR101266549B1 (ko) * 2006-10-20 2013-05-24 시노팜 싱가포르 피티이 리미티드 결정형 무수 도세탁셀을 제조하는 방법
FR2926551A1 (fr) * 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
EP2688877B1 (en) 2011-04-12 2017-03-08 Teva Pharmaceuticals International GmbH Solid state forms of cabazitaxel and processes for preparation thereof
EP2548905A1 (de) 2011-07-18 2013-01-23 Bayer MaterialScience AG Verfahren zur Aktivierung von Doppelmetallcyanidkatalysatoren zur Herstellung von Polyetherpolyolen
TWI526437B (zh) 2011-09-09 2016-03-21 台灣神隆股份有限公司 卡巴他賽之結晶型
JP6025861B2 (ja) 2011-12-13 2016-11-16 アベンティス・ファーマ・ソシエテ・アノニム カバジタキセルの結晶形およびこれを調製するための方法
EP2822932A2 (en) 2012-03-08 2015-01-14 IVAX International GmbH Solid state forms of cabazitaxel and processes for preparation thereof
CN102675257B (zh) 2012-05-10 2014-07-02 上海金和生物技术有限公司 一种卡巴他赛晶体及其制备方法
CN102898406B (zh) * 2012-11-02 2014-12-03 上海金和生物技术有限公司 一种卡巴他赛晶体及其制备方法

Also Published As

Publication number Publication date
WO2015058961A1 (en) 2015-04-30
SI3060556T1 (sl) 2017-10-30
IL245260B (en) 2018-11-29
JP2016534065A (ja) 2016-11-04
JP6698803B2 (ja) 2020-05-27
EP3060556B1 (en) 2017-08-02
SG11201603168WA (en) 2016-05-30
CL2016000951A1 (es) 2016-11-25
IL245260A0 (en) 2016-06-30
PT3060556T (pt) 2017-11-10
AU2014339222A1 (en) 2016-05-12
US9586919B2 (en) 2017-03-07
EP2865675A1 (en) 2015-04-29
RU2672110C2 (ru) 2018-11-12
ES2645478T3 (es) 2017-12-05
US20160244420A1 (en) 2016-08-25
AU2014339222B2 (en) 2017-12-14
CA2928305C (en) 2021-06-15
HUE035010T2 (en) 2018-03-28
BR112016007646B1 (pt) 2022-12-27
EP3060556A1 (en) 2016-08-31
CN105849093A (zh) 2016-08-10
MX363334B (es) 2019-03-19
MX2016005231A (es) 2016-08-11
RU2016115538A3 (pt) 2018-06-14
KR20210158417A (ko) 2021-12-30
KR20160063356A (ko) 2016-06-03
PL3060556T3 (pl) 2018-01-31
JP2019055989A (ja) 2019-04-11
DK3060556T3 (en) 2017-09-04
CA2928305A1 (en) 2015-04-30
RU2016115538A (ru) 2017-10-26

Similar Documents

Publication Publication Date Title
CY1121549T1 (el) Ενωσεις 1-αρυλκαρβονυλ-4-oξυ-πιπεριδινης χρησιμες για την αγωγη νευροεκφυλιστικων παθησεων
CY1119731T1 (el) Διαδικασια για την παρασκευη παραγωγων χολικου οξεος
BR112017017396A2 (pt) derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos
CR20130534A (es) Nuevos derivados de imidazol útiles para el tratamiento de artritis
BR112017010354A2 (pt) compostos de triazolopirimidina e usos dos mesmos
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
EA201590453A1 (ru) Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201690094A1 (ru) Ингибиторы syk
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
BR112012023950A2 (pt) formas cristalinas de um macrolídeo, e usos dos mesmos
DOP2014000012A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
CY1116439T1 (el) Τριαζολοπυριδινες
CU20130036A7 (es) Triazina-oxidazoles
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
BR112012024822B8 (pt) Composto, uso de um composto e composição farmacêutica
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
BR112015008037A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
EA201200471A1 (ru) Простые эфирные производные бициклических гетероарилов
BR112013011593A2 (pt) cristal de derivado de morfinan 7-carbamoíla-6,7-insaturada e método para produzir o mesmo
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
EA201391371A1 (ru) Фармацевтическая композиция ситаглиптина
EA201600394A1 (ru) Трициклические соединения пиперидина
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/10/2014, OBSERVADAS AS CONDICOES LEGAIS